Meeting News
-
Celebrate the IASLC Foundation’s Impact
Join your colleagues in recognizing more than a decade of lung cancer research made possible by the IASLC Foundation at WCLC 2025.
-
Step it Up at WCLC 2025 in Barcelona
Track your steps, win prizes, and support the IASLC Foundation by participating in the 2025 Wellness Challenge.
-
Know Before You Go: Your Guide to Navigating Barcelona
Plan ahead for WCLC 2025 with this guide to local transportation, cultural norms, and important travel documents.
-
Spotlight on the WCLC 2025 Talent Showcase
Prepare to be amazed as members of the global lung cancer community take center stage in Barcelona.
-
A Pragmatic Approach to Trial Design
Although the primary finding was not what investigators had hoped for, recent presentations by Drs. Karen Reckamp and Konstantin H. Dragnev highlighted Pragmatica-Lung’s success as a model for future trials.
-
SACHI Trial Results: Savolitinib-Osimertinib Combo Improves PFS in MET-Amplified EGFR-Mutated NSCLC
Dr. Shun Lu said savolitinib plus osimertinib offers a potential new chemo-free treatment option for patients after progression on first-line treatment.
-
IMpower010 Trial Update Highlights Long-Term Benefits of Adjuvant Atezolizumab in Resected NSCLC
The updated data and a recently presented exploratory analysis show the benefits varied based on PD-L1 expression, which may be influenced by a variety of genomic alterations.
-
Tarlatamab Emerges as New Standard of Care in Second-Line SCLC, with Significant Gains in OS, PFS
Dr. Charles M. Rudin, who presented data from the DeLLphi-304 trial at ASCO 2025, noted that patient-reported outcomes also showed improvements in common symptoms, including dyspnea and cough, with fewer toxicities of grade 3 or higher.
-
A Paradigm Shift: Final 5-Year Overall Survival Results from CheckMate 816 in Resectable NSCLC
Dr. Patrick Forde recently presented milestone data from the trial that confirms the benefit of neoadjuvant-only chemoimmunotherapy for the treatment of resectable lung cancer.
-
Lurbinectedin and Atezolizumab Combo Demonstrates Survival Benefit in ES-SCLC
Dr. Luis G. Paz-Ares reviewed new IMforte trial results at the 2025 ASCO Annual Meeting.
View ILCN Archives
Provider Resources